Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate(Timoptol&reg;-XE ophthalmic Solution 0.5%) ,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5%

Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate(Timoptol&reg;-XE ophthalmic Solution 0.5%) ,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5% - Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5%

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004224

Enrollment

Registered

2010-09-17

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Investigation for efficacy,safety a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5% once daily for a month into one of a subject

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 At Measurement for IOP base line, patient who has to fill over or equal 20 years-old 2 Out of consideration for gender, inpatient and outpatient 3.Patient, who has been managed Travoprost 0.004% and Timolol 0.5% or long-acting 2% Carteolol over a month till measurement of IOP baseline. 4.Patient, who has been accepted by Dr as candidate of switching to combination drug .

Exclusion criteria

Exclusion criteria: 1Patient, who has been managed due to chronic or replace uvetis, sceritis and herpes cornea. 2.Patient, who has been managed by traumatic diseases,ocular surgery,laser operation within 3 months. 3.Patinet, who is not available to measure by Aplanation tonomater. 4.Patinet, who has irritation for PG eye solution, related PG eye solution and Benzalkonium chloride(BAC). 5.Patient, who is severe Alzheimer. 6.Patinet, who has been managed by oral CAI or steroid eye solution. 7.Patinet, who has been applied other IOP reductive drug.

Design outcomes

Primary

Measure	Time frame
IOP reduction	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactEiichi Nomura

Yokohama City University Hospital Department of Ophthalmology

045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Comparison study for ocular hypotensive effect of switching from Travoprost 0.004% and Timolol maleate(Timoptol&amp;reg;-XE ophthalmic Solution 0.5%) ,Travoprost 0.004% and long-acting 2% Carteolol to a conbined opthalmic solution Travoprost 0.004%/Timolol 0.5%